MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK) today announced the commencement of a multi-center clinical study of OPKO’s point-of-care diagnostic test for prostate specific antigen (PSA) utilizing its proprietary diagnostic platform. OPKO intends to submit its application to the U.S. Food and Drug Administration for approval of the assay in 2012.
